Recent Updates
Recently added Catalysts
KNSA Positive Sentiment

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Tuesday, November 26, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced that its management will join a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024. The event will begin at 9:35 a.m. Eastern Time, with a live webcast available on Kiniksa's website. Following the presentation, a replay will be accessible approximately 48 hours later. Kiniksa focuses on developing therapeutic medicines for patients with significant unmet medical needs, particularly in autoimmune and cardiovascular conditions.
Price reaction · baseline $21.8 (2024-11-25 close) · hit after-hours · clean, no other KNSA news in the window
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Kiniksa Pharmaceuticals is actively participating in significant industry conferences.
  • The company is focused on addressing unmet medical needs with its therapies.
  • Kiniksa offers a range of immune-modulating assets with potential for differentiation.

Full Press Release Details

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor Contact
Jonathan Kirshenbaum
jkirshenbaum@kiniksa.com
Kiniksa Media Contact

Frequently Asked Questions

When is Kiniksa's fireside chat at HealthCONx Conference?

Kiniksa's fireside chat is scheduled for December 3, 2024, at 9:35 a.m. ET.

Where can I watch Kiniksa's presentation live?

The live webcast will be available in the Investors section of Kiniksa's website.

Will there be a replay of Kiniksa's fireside chat?

Yes, a replay will be accessible on Kiniksa's website within 48 hours after the event.

What does Kiniksa Pharmaceuticals focus on?

Kiniksa is dedicated to developing therapeutic medicines for unmet medical needs.

What types of conditions does Kiniksa target?

Kiniksa targets underserved cardiovascular and autoimmune conditions.

ShareAdd on Google
Tags: KNSA Viatris Investor Conferences Healthcare Kiniksa Pharmaceuticals HealthCONx Conference biopharmaceuticals therapeutic medicines
Last updated: Nov 26, 2024

Biotech snapshot

Cash runway
$468M liquidity · $0M/mo burn
Low dilution risk
Lead asset
KPL-404Phase 2
Arthritis, Rheumatoid →